Andrea L. Benedet

Jul 29, 2024 | medrxiv.org | Nicholas Ashton |Andrea L. Benedet |Ilaria Pola |Guglielmo Di Molfetta

HZ has served at scientific advisory boards and/or as a consultant for Abbvie, Acumen, Alector, Alzinova, ALZPath, Amylyx, Annexon, Apellis, Artery Therapeutics, AZTherapies, Cognito Therapeutics, CogRx, Denali, Eisai, LabCorp, Merry Life, Nervgen, Novo Nordisk, Optoceutics, Passage Bio, Pinteon Therapeutics, Prothena, Red Abbey Labs, reMYND, Roche, Samumed, Siemens Healthineers, Triplet Therapeutics, and Wave, has given lectures in symposia sponsored by Alzecure, Biogen, Cellectricon,...

Aug 3, 2023 | alz-journals.onlinelibrary.wiley.com | Joseph Therriault |Cecile Tissot |João Pedro Ferrari-Souza |Andrea L. Benedet

Abstract INTRODUCTION Phosphorylated tau (p-tau) biomarkers have been recently proposed to represent brain amyloid-β (Aβ) pathology. Here, we evaluated the plasma biomarkers' contribution beyond the information provided by demographics (age and sex) to identify Aβ and tau pathologies in individuals segregated as cognitively unimpaired (CU) and impaired (CI). METHODS We assessed 138 CU and 87 CI with available plasma p-tau231, 217+, and 181, Aβ42/40, GFAP and Aβ- and tau-PET.